ImmuPharma (LON:IMM) Shares Up 34.1% - Still a Buy?

Key Points

• ImmuPharma's stock price surged by 34.1% during mid-day trading, reaching a high of GBX 11.50 ($0.16) from a previous close of GBX 8.06 ($0.11).
• The company, with a market cap of £54.02 million, reported a negative earnings per share (EPS) of GBX (0.38), and is projected to have a yearly EPS of -339.0000022.
• ImmuPharma specializes in developing peptide-based therapeutics, notably the first-in-class immunomodulator Lupuzor™ for treating Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price traded up 34.1% during mid-day trading on Tuesday . The stock traded as high as GBX 11.50 ($0.16) and last traded at GBX 10.81 ($0.15). 53,526,668 shares traded hands during trading, an increase of 605% from the average session volume of 7,597,544 shares. The stock had previously closed at GBX 8.06 ($0.11).

ImmuPharma Stock Up 34.1%

The stock has a market cap of £54.02 million, a PE ratio of -1,214.61 and a beta of 1.53. The firm has a 50-day simple moving average of GBX 2.38 and a 200-day simple moving average of GBX 2.70.

ImmuPharma (LON:IMM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, research analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.